Most of adult patients with chronic immune thrombocytopenic purpura (ITP) that was refractory or relapsed to high-dose corticosteroid have been treated with splenectomy as a 2nd line treatment. However, these patients may have increased morbidity and mortality according to the operation and the increased risk of infection for a lifetime after splenectomy. Despite of the above risks, 30∼40% of these patients can't maintain remission. Furthermore, the remission rate after splenectomy is relatively lower in patients with corticosteroid-refractory chronic ITP than that in those patients with corticosteroidresponsiveness. We studied whether danazol, an attenuated androgen, is useful or safe as 2nd line treatment for chronic ITP instead of splenectomy and which factors are associated with the response to danazol. Methods: Among the patients with chronic ITP who failed corticosteroid therapy in our hospital, 28 patients who received danazol as the 2nd line treatment were analyzed retrospectively. A complete response was defined that the platelet count was increased to 150×10 3 /μL, and a partial response was
CI: 182∼478) by the Kaplan-Meiyer method. For the danazol-responsive patients, 9 patients (40.9%) remained in remission and 13 patients (59.1%) relapsed. Grade 3∼4 toxicity was observed in two patients and three patients stopped danazol because of adverse effects. Hepatotoxicity was the most common toxicity. Conclusion: Our findings suggest that danazol is a beneficial, safe choice as the 2nd line treatment for patients with chronic ITP that was refractory or relapsed to corticosteroid. (Table  1) .
치료결과
만성 ITP 진단 후 다나졸 투여까지의 중앙기간은 56 Fig. 1 . Event-free survival in 28 patients with danazol therapy. An event was defined by the lack of response, relapse, and major side effect leading to drug withdrawal. Survival was calculated from the first day of danazol therapy to the day of the event. (Table 2) . Kaplan-Meiyer method에 의한 중앙관해유지기간은 330일(95% 신뢰구간: 182∼478일)이었다 (Fig. 1) (Fig. 2) . 
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